Company: TVRD
Filing Date: 2025-02-14
Form Type: 424B3
Source: 0001104659-25-014310
Chunk: 572

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-02-14
Form: 424B3
Chunk 572
---
 Expense on Liability Related to the Sales of Future Royalties and Milestones**

| ​                                                                                          
 ​                                                                                          
 ​                                                                                          | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Three Months EndedSeptember 30, 
 2024                            
 Dollar amounts in thousands     |   |       |   | ​ | ​ | 2023 |   |   |   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​        
 % change 
 ​        | ​ 
 ​ | ​   
 ​   | ​ 
 ​ | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | Nine Months EndedSeptember 30, 
 2024                           
 Dollar amounts in thousands    |   |       |   | ​ | ​ | 2023 |   |   |   | ​ 
 ​ 
 ​ | ​ 
 ​ 
 ​ | ​        
 % change 
 ​        | ​ 
 ​ | ​   
 ​   | ​ 
 ​ | ​ 
 ​ 
 ​ |
|:-------------------------------------------------------------------------------------------|:--|:--|:--------------------------------|:--|------:|:--|:--|:--|:-----|:--|:--|:--|:--|:--|:---------|:--|:----|:--|:--|:--|:-------------------------------|:--|------:|:--|:--|:--|:-----|:--|:--|:--|:--|:--|:---------|:--|:----|:--|:--|
| Non-cash interest expense on liability related to sales of future royalties and milestones | ​ | ​ | ​                               | $ | 1,960 | ​ | ​ | ​ | ​    | $ | — | ​ | ​ | ​ | ​        | ​ | N/A | ​ | ​ | ​ | ​                              | $ | 5,852 | ​ | ​ | ​ | ​    | $ | — | ​ | ​ | ​ | ​        | ​ | N/A | ​ | ​ |

329

TABLE OF CONTENTS

Cara recognized $2.0 million and $5.9 million of non-cash interest expense on the liability related to sales of future royalties and milestones for the three and nine months ended September 30, 2024, respectively, which represented imputed interest on the carrying value of the liability to HCR, and the amortization of the related issuance costs associated with the Original HCR Agreement. There was no non